Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 15, 2025 09:00 ET | Source: Lyell Immunopharma, Inc

Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for LYL314 for the Treatment of Relapsed and/or Refractory Large B-Cell Lymphoma

RMAT designation was granted based on promising clinical data from the ongoing Phase 1/2 trial of LYL314 in patients with relapsed and/or refractory large B-cell lymphoma.RMAT designation recognizes...
January 09, 2025 09:00 ET | Source: Lyell Immunopharma, Inc

Lyell to Highlight Vision for its Next-Generation CAR T-Cell Therapy Pipeline at 43rd Annual JP Morgan Healthcare Conference

Accelerating IMPT-314 in large B-cell lymphoma; remain on track to initiate pivotal trial in the 3rd line+ setting in 2025 and expect to initiate a pivotal trial in the 2nd line by early...
November 05, 2024 09:30 ET | Source: Lyell Immunopharma, Inc

Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting

SOUTH SAN FRANCISCO, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for...
March 19, 2024 07:00 ET | Source: Research Nester

Non-Hodgkin Lymphoma Therapeutics Market revenue to hit USD 20 Billion by 2036, says Research Nester

New York , March 19, 2024 (GLOBE NEWSWIRE) -- The global non-hodgkin lymphoma therapeutics market size is projected to grow at a CAGR of over 8% from 2024 to 2036. The market is expected to garner a...
May 31, 2023 13:00 ET | Source: DelveInsight Business Research LLP

B-Cell Lymphoma Clinical Trial Pipeline Insights: DelveInsight Evaluates a Robust Pipeline as 160+ Influential Pharma Players to Set Foot in the Domain

New York, USA, May 31, 2023 (GLOBE NEWSWIRE) -- B-Cell Lymphoma Clinical Trial Pipeline Insights: DelveInsight Evaluates a Robust Pipeline as 160+ Influential Pharma Players to Set Foot in the...
September 22, 2015 07:00 ET | Source: Rhizen Pharmaceuticals SA

Rhizen Pharmaceuticals S.A. announces initiation of Phase 2 study of RV1001 in dogs with T- or B-cell Lymphoma

La Chaux-de-Fonds, Switzerland, Sept. 22, 2015 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A. has announced the initiation of Phase 2 study of RV1001, a novel, oral selective inhibitor of PI3K...
October 02, 2013 08:35 ET | Source: MMRGlobal, Inc.

MMRGlobal Receives Additional Biotech Patent Protection in U.S., Mexico and Japan for Cancer Vaccines

LOS ANGELES, CA--(Marketwired - Oct 2, 2013) - MMRGlobal, Inc. (OTCQB: MMRF) ("MMR"), a leading provider of Personal Health Records (PHRs), MyEsafeDepositBox storage solutions and electronic...
June 25, 2013 08:35 ET | Source: MMRGlobal, Inc.

MMRGlobal Receives Cancer Fighting Vaccine Patent in Hong Kong

LOS ANGELES, CA--(Marketwired - Jun 25, 2013) - MMRGlobal, Inc. (OTCQB: MMRF) ("MMR") today announced that it has received another biotechnology patent, this one in Hong Kong. The Company has...
April 15, 2013 08:35 ET | Source: MMRGlobal, Inc.

MMRGlobal Announces U.S. Patent for Cancer Fighting Anti-CD20 Monoclonal Antibody

LOS ANGELES, CA--(Marketwired - Apr 15, 2013) - MMRGlobal, Inc. (OTCQB: MMRF) ("MMR") today announced that the United States Patent and Trademark Office has issued a Notice of Allowance...
November 19, 2012 08:35 ET | Source: MMRGlobal, Inc.

MMRGlobal Targets Phase 3 Biotech Companies to Combine Assets With Life Sciences Group

LOS ANGELES, CA--(Marketwire - Nov 19, 2012) - MMRGlobal, Inc. (OTCBB: MMRF) today announced that through its wholly owned subsidiary, MMR Life Sciences Group, the Company plans on exploiting its...

Next Page keyboard_arrow_right